Coagulation in sepsis: All bugs bite equally

Critical Care

Volumn 8, Issue 2, 2004, Pages 99-100

  Levi, Marcel ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BLOOD CLOTTING; DISEASE SEVERITY; FIBRINOLYSIS; HUMAN; INFLAMMATION; MICROORGANISM; NOTE; PATHOGENESIS; PRIORITY JOURNAL; SEPSIS;

BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; CLINICAL TRIALS, PHASE III; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; INFLAMMATION; PROGNOSIS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 1842478877     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc2816     Document Type: Note

References (15)

1. Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre P-F, Dhainaut J-F, for the PROWESS Sepsis Study Group: Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 2004, 8:R82-R90.
2. Levi M, ten Cate H: Disseminated intravascular coagulation. N Engl J Med 1999, 341:586-592.
3. Levi M, Keller TT, van Gorp E, ten Cate H: Infection and inflammation and the coagulation system. Cardiovasc Res 2003, 60: 26-39.
4. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
5. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM; KyberSept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878.
6. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA; OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003, 290:238-247.
7. Levi M, de Jonge E, van der Poll T: Recombinant human activated protein C (Xigris). Int J Clin Pract 2002, 56:542-545.
8. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, Helterbrand JD: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001, 29:2051-2059.
9. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson BR, Brandt JT, Sundin D, Levi M: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, in press.
10. Bone RC: Gram-positive organisms and sepsis. Arch Intern Med 1994, 154:26-34.
11. Mohanty D, Ghosh K, Nandwani SK, Shetty S, Phillips C, Rizvi S, Parmar BD: Fibrinolysis, inhibitors of blood coagulation, and monocyte derived coagulant activity in acute malaria. Am J Hematol 1997, 54:23-29.
12. Suharti C, van Gorp EC, Setiati TE, Dolmans WM, Djokomoeljanto RJ, Hack CE, ten CH, van der Meer JW: The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. Thromb Haemost 2002, 87:42-46.
13. Sriskandan S, Kemball-Cook G, Moyes D, Canvin J, Tuddenham E, Cohen J: Contact activation in shock caused by invasive group A Streptococcus pyogenes. Crit Care Med 2000, 28: 3684-3691.
14. Netea MG, Kullberg BJ, Joosten LA, Sprong T, Verschueren I, Boerman OC, Amiot F, van den Berg WB, Van der Meer JW: Lethal Escherichia coli and Salmonella typhimurium endotoxemia is mediated through different pathways. Eur J Immunol 2001, 31:2529-2538.
15. Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan SB, Williams MD, Graham DE, Nelson DR, Levy H, Bernard GR: Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003, 37:50-58.